Dihexa
Peptide ·Exploratory record · not publication-reviewed ·Updated July 13, 2026
Dihexa is an angiotensin IV-derived peptidomimetic that potentiates hepatocyte growth factor signaling at c-Met in preclinical studies. It is not FDA-approved and has no adequate published human safety or efficacy trials. Because HGF/c-Met signaling is relevant to cancer biology, self-use is medically inappropriate.
Exploratory record, not a reviewed medical publication.
See the editorial and medical-review policies for the publication gate.
This safety record covers a controlled, investigational, or otherwise out-of-scope substance. It remains available for reference, but it is not part of NutriStack's public supplement publication set.
What the research says.
A quick, data-only summary. The full evidence, dosing, and sources are below.
Dihexa is a peptide most often used for preclinical synaptogenesis research, hgf/c-met signaling tool compound, animal memory-model effects. NutriStack rates the overall evidence as insufficient. A typical adult dose is No FDA-approved human dose; no human dose established, commonly taken as not recommended for human use; laboratory research reagent only. This profile indexes 3 sources.
- Unknown human toxicity
- Headache or agitation if CNS-active
- Theoretical tumor-growth concern
- Active cancer or prior cancer without oncology clearance1
- Pregnancy and breastfeeding
The bottom line
Evidence rating insufficient. Most-documented uses: preclinical synaptogenesis research, hgf/c-met signaling tool compound, animal memory-model effects. 3 sources indexed (2010–2014), with 0 interaction records on file.
How it works, mechanistically.
Core mechanism
Dihexa binds hepatocyte growth factor and appears to facilitate HGF-dependent c-Met activation, hippocampal spinogenesis, synaptogenesis, and memory effects in animal models. The same pathway supports cell growth, motility, and repair, and dysregulated c-Met signaling is implicated in malignancy. Preclinical potency does not establish safe nootropic dosing.2
Dosing & protocol.
Peptides are generally not reliably orally bioavailable unless a specific studied oral formulation is used. Human use of research-grade products is not appropriate.
What it actually costs.
Real-world pricing across three quality tiers. Assumes Laboratory Research Reagent.
Research-market pricing is not a dosing recommendation; human use is not FDA-approved unless specifically stated. Updated 2026-06-04.
Full safety detail.
Side effects
- Unknown human toxicity
- Headache or agitation if CNS-active
- Theoretical tumor-growth concern
- Unknown cardiovascular effects
- Product mislabeling risk
Contraindications
- Active cancer or prior cancer without oncology clearance1
- Pregnancy and breastfeeding
- Any unsupervised human use
- Bipolar disorder, psychosis, or severe neurologic disease without specialist care
- Research-grade products for human use
Sources, by evidence tier.
Numbered references. Citations throughout the page link here.
Reviews & position papers
1- 1Targeting the HGF/Met signalling pathway in cancerCecchi F et al. · European Journal of Cancer · 2010
HGF/Met pathway is important in cancer biology
Mechanistic & preclinical
2- 2The procognitive and synaptogenic effects of angiotensin IV-derived peptides are dependent on activation of the hepatocyte growth factor/c-met systemMcCoy AT et al. · Journal of Pharmacology and Experimental Therapeutics · 2014
Dihexa potentiated HGF/c-Met signaling
- 3Facilitation of hippocampal synaptogenesis and spatial memory by C-terminal truncated Nle1-angiotensin IV analogsBenoist CC et al. · Journal of Pharmacology and Experimental Therapeutics · 2011
Angiotensin IV analogs improved memory models
Common questions.
Quick answers about Dihexa, drawn from the data on this page.
What is Dihexa?
Dihexa is an angiotensin IV-derived peptidomimetic that potentiates hepatocyte growth factor signaling at c-Met in preclinical studies. It is not FDA-approved and has no adequate published human safety or efficacy trials. Because HGF/c-Met signaling is relevant to cancer biology, self-use is medically inappropriate.
What is Dihexa used for?
Commonly cited benefits of Dihexa include: Preclinical synaptogenesis research; HGF/c-Met signaling tool compound; Animal memory-model effects; No human clinical indication. NutriStack rates the overall evidence as insufficient.
What is a typical dose of Dihexa?
A typical adult dose of Dihexa is No FDA-approved human dose; no human dose established. The commonly recommended form is Not recommended for human use; laboratory research reagent only. These are general ranges, not personalized advice; confirm the right dose with a clinician.
What are the side effects of Dihexa?
Reported side effects include unknown human toxicity, headache or agitation if cns-active, theoretical tumor-growth concern, unknown cardiovascular effects, product mislabeling risk. This is educational information; check with a healthcare professional before use.
How strong is the evidence for Dihexa?
NutriStack rates this as Insufficient, meaning the body of evidence reviewed in NutriStack's tiering framework. Full tier criteria are at https://nutristackapp.com/methodology/evidence-tiers.
Use this with your stack
Dihexa in NutriStack.
Add it to your stack, see how it interacts with everything else you take, and get a Stack Score that updates the moment it does.